- Home
- ZENV vs IMA Comparison
ZENV vs IMA Comparison
Compare ZENV & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- IMA
- Stock Information
- Founded
- ZENV 2005
- IMA 2019
- Country
- ZENV Brazil
- IMA United States
- Employees
- ZENV N/A
- IMA N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- IMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZENV Technology
- IMA Health Care
- Exchange
- ZENV Nasdaq
- IMA Nasdaq
- Market Cap
- ZENV 79.7M
- IMA 92.2M
- IPO Year
- ZENV 2021
- IMA N/A
- Fundamental
- Price
- ZENV $1.43
- IMA $8.27
- Analyst Decision
- ZENV
- IMA
- Analyst Count
- ZENV 0
- IMA 0
- Target Price
- ZENV N/A
- IMA N/A
- AVG Volume (30 Days)
- ZENV 104.7K
- IMA 87.8K
- Earning Date
- ZENV 11-17-2025
- IMA 11-15-2025
- Dividend Yield
- ZENV N/A
- IMA N/A
- EPS Growth
- ZENV N/A
- IMA N/A
- EPS
- ZENV N/A
- IMA N/A
- Revenue
- ZENV $201,426,369.00
- IMA $4,300,000.00
- Revenue This Year
- ZENV $6.49
- IMA N/A
- Revenue Next Year
- ZENV $3.82
- IMA N/A
- P/E Ratio
- ZENV N/A
- IMA N/A
- Revenue Growth
- ZENV 24.80
- IMA N/A
- 52 Week Low
- ZENV $1.02
- IMA $7.57
- 52 Week High
- ZENV $3.03
- IMA $23.28
- Technical
- Relative Strength Index (RSI)
- ZENV 54.00
- IMA N/A
- Support Level
- ZENV $1.26
- IMA N/A
- Resistance Level
- ZENV $1.48
- IMA N/A
- Average True Range (ATR)
- ZENV 0.08
- IMA 0.00
- MACD
- ZENV 0.02
- IMA 0.00
- Stochastic Oscillator
- ZENV 90.91
- IMA 0.00
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About IMA ImageneBio Inc. Common Stock
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.